Switch theme
Sign up to access all valuation multiples
Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abclon has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Abclon achieved revenue of $1.6M and an EBITDA of -$9.4M.
Abclon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abclon valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $1.6M | XXX | XXX | XXX |
| Gross Profit | $1.6M | $1.5M | XXX | XXX | XXX |
| Gross Margin | 77% | 94% | XXX | XXX | XXX |
| EBITDA | -$6.6M | -$9.4M | XXX | XXX | XXX |
| EBITDA Margin | -315% | -590% | XXX | XXX | XXX |
| Net Profit | -$6.3M | -$8.7M | XXX | XXX | XXX |
| Net Margin | -300% | -546% | XXX | XXX | XXX |
| Net Debt | $4.3M | $0.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Abclon's stock price is KRW 9280 (or $6).
Abclon has current market cap of KRW 162B (or $110M), and EV of KRW 158B (or $107M).
See Abclon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $107M | $110M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Abclon has market cap of $110M and EV of $107M.
Abclon's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Abclon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Abclon and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $107M | XXX | XXX | XXX |
| EV/Revenue | 67.3x | XXX | XXX | XXX |
| EV/EBITDA | -11.4x | XXX | XXX | XXX |
| P/E | -9.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAbclon's NTM/LTM revenue growth is n/a
Abclon's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Abclon's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Abclon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Abclon and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -24% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -590% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 572% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 712% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abclon acquired XXX companies to date.
Last acquisition by Abclon was XXXXXXXX, XXXXX XXXXX XXXXXX . Abclon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Abclon founded? | Abclon was founded in 2010. |
| Where is Abclon headquartered? | Abclon is headquartered in South Korea. |
| Who is the CEO of Abclon? | Abclon's CEO is Mr. Jong-seo Lee. |
| Is Abclon publicy listed? | Yes, Abclon is a public company listed on KRX. |
| What is the stock symbol of Abclon? | Abclon trades under 174900 ticker. |
| When did Abclon go public? | Abclon went public in 2017. |
| Who are competitors of Abclon? | Similar companies to Abclon include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Abclon? | Abclon's current market cap is $110M |
| What is the current revenue growth of Abclon? | Abclon revenue growth between 2023 and 2024 was -24%. |
| Is Abclon profitable? | Yes, Abclon is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
